Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity ...

Humacyte's stock struggles despite FDA approval for Symvess, with financial concerns and slow adoption impacting future ...

Shares of Humacyte Inc. (HUMA) tumbled nearly 11% on Friday despite the company reporting a narrower-than-expected loss. The ...

The extracellular matrix (ECM) is a dynamic bioactive acellular environment, but its critical role in driving solid tumor development, immune-cell exclusion and therapy resistance is typically ...

Humacyte, Inc.'s stock fell 25% amid $50M fundraising and safety concerns on FDA-approved Symvess. Click for this updated ...

BTIG lowered the firm’s price target on Humacyte (HUMA) to $8 from $10 and keeps a Buy rating on the shares post the Q4 report. The firm cites ...

An alternative to synthetic materials would be a biomaterial that could be used in the design of a tissue-engineered graft. We demonstrate that a small-diameter (4 mm) graft constructed from a ...

North Carolina's life sciences ecosystem is thriving, thanks in no small part to the leadership and innovation of women ...

"We developed a cell-free—or acellular—material that dynamically mimics the behavior of ECMs, which are key building blocks of mammalian tissues that are crucial for tissue structure and cell ...

MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, ...

The publication, titled "Budget impact model of acellular tissue engineered vessel for the repair of extremity arterial trauma when autologous vein is not feasible,” reported that Symvess was ...